FindMyKOL
Clinical trialNCT04302896CompletedPhase Early 1Interventional

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

NCT04302896 is a phase early 1 interventional trial sponsored by Rhonda Brand. As of 21 Nov 2026, it is completed. It studies Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil in HIV and Medication Adherence. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2020 and a primary completion date of 30 Sept 2021.

SponsorRhonda BrandEnrollment30HIVMedication Adherence
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04302896
FieldValue
Registry IDNCT04302896
StatusCompleted
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorRhonda Brand
Enrollment30
Registered sites1
Countries1
ConditionsHIV and Medication Adherence
DrugsDolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil
Start31 Aug 2020
Primary completion30 Sept 2021
Study completion30 Sept 2021
Last update posted3 Mar 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-center, open label study to identify adherence levels of commonly prescribed FDA-approved antiretroviral agents by tracking the decline of drug concentrations in plasma, urine and saliva following abrupt drug cessation in HIV-negative adults. Results from this study may provide support for development of a point of care urine testing device to monitor drug adherence.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • Hiv/aids Clinical Research Unit / University of Pittsburgh

    Pittsburgh

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04302896

Each answer restates registry values shown on this page.

What is NCT04302896?

NCT04302896 is a phase early 1 interventional trial sponsored by Rhonda Brand. It studies Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil in HIV and Medication Adherence.

Who leads NCT04302896?

The registry names Ken Ho, MD (principal investigator, University of Pittsburgh) and Rhonda Brand, PhD (study chair, University of Pittsburgh) as overall officials.

Where does NCT04302896 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04302896 study?

The registered drug and biological interventions are Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil.

When did NCT04302896 end?

The registry lists a primary completion date of 30 Sept 2021 and a study completion date of 30 Sept 2021. The sponsor last updated the record on 3 Mar 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.